tradingkey.logo
๎™

QuidelOrtho Corp

QDEL
29.810USD
+0.860+2.97%
์ข…๊ฐ€ย 12/22, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
2.02B์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ QuidelOrtho Corp ํšŒ์‚ฌ

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.

QuidelOrtho Corp ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ QDEL
ํšŒ์‚ฌ ์ด๋ฆ„QuidelOrtho Corp
์ƒ์žฅ์ผFeb 01, 1991
CEOBlaser (Brian J)
์ง์› ์ˆ˜6600
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒFeb 01
์ฃผ์†Œ9975 Summers Ridge Road
๋„์‹œSAN DIEGO
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ92121
์ „ํ™”18585521100
์›น์‚ฌ์ดํŠธhttps://www.quidelortho.com/
์ข…๋ชฉ ์ฝ”๋“œ QDEL
์ƒ์žฅ์ผFeb 01, 1991
CEOBlaser (Brian J)

QuidelOrtho Corp์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9.68%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+7.29%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+75.18%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
32.03K
+8.95%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+35.98%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
15.02K
+5.26%
Mr. Brian J. Blaser
Mr. Brian J. Blaser
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.45K
--
Mr. John R. Chiminski
Mr. John R. Chiminski
Independent Director
Independent Director
2.52K
--
Sergio Gadaleta
Sergio Gadaleta
Senior Vice President - Clinical and Regulatory Affairs
Senior Vice President - Clinical and Regulatory Affairs
--
--
Devon Burek
Devon Burek
Senior Vice President - Global Quality
Senior Vice President - Global Quality
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9.68%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+7.29%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+75.18%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
32.03K
+8.95%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+35.98%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
15.02K
+5.26%

์ˆ˜์ต ๋ถ„์„

ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Oct 6
ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
์‚ฌ์—…๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
Labs
369.70M
60.22%
Immunohematology
132.30M
21.55%
Point-of-Care
93.00M
15.15%
Donor Screening
13.30M
2.17%
Molecular Diagnostic Solutions
5.60M
0.91%
์ง€์—ญ๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
North America
310.70M
50.61%
Other
132.50M
21.58%
EMEA
87.30M
14.22%
China
83.40M
13.59%
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
์‚ฌ์—…๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
Labs
369.70M
60.22%
Immunohematology
132.30M
21.55%
Point-of-Care
93.00M
15.15%
Donor Screening
13.30M
2.17%
Molecular Diagnostic Solutions
5.60M
0.91%

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Nov 17
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Nov 17
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
T. Rowe Price Investment Management, Inc.
16.21%
BlackRock Institutional Trust Company, N.A.
13.72%
The Vanguard Group, Inc.
11.19%
Rubric Capital Management LP
6.83%
Fidelity Management & Research Company LLC
6.54%
๊ธฐํƒ€
45.52%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
T. Rowe Price Investment Management, Inc.
16.21%
BlackRock Institutional Trust Company, N.A.
13.72%
The Vanguard Group, Inc.
11.19%
Rubric Capital Management LP
6.83%
Fidelity Management & Research Company LLC
6.54%
๊ธฐํƒ€
45.52%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Investment Advisor
68.41%
Investment Advisor/Hedge Fund
35.84%
Hedge Fund
14.73%
Research Firm
2.25%
Pension Fund
1.07%
Individual Investor
0.95%
Private Equity
0.76%
Bank and Trust
0.61%
Sovereign Wealth Fund
0.52%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Oct 1
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Oct 1
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q3
656
79.44M
116.95%
-23.17M
2025Q2
684
78.51M
115.63%
-21.42M
2025Q1
726
76.59M
113.26%
-21.60M
2024Q4
747
75.07M
111.30%
-13.02M
2024Q3
744
73.58M
109.44%
-4.02M
2024Q2
767
70.18M
104.79%
-7.57M
2024Q1
799
67.05M
100.24%
-5.28M
2023Q4
828
68.21M
102.09%
-2.95M
2023Q3
842
70.19M
105.17%
-4.01M
2023Q2
860
68.99M
103.61%
-6.94M
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
T. Rowe Price Investment Management, Inc.
11.14M
16.4%
-310.96K
-2.72%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
9.28M
13.67%
+1.73M
+22.86%
Jun 30, 2025
The Vanguard Group, Inc.
7.77M
11.44%
+1.04M
+15.55%
Jun 30, 2025
Rubric Capital Management LP
4.64M
6.83%
-1.50M
-24.47%
Jun 30, 2025
Fidelity Management & Research Company LLC
2.56M
3.76%
+1.30M
+103.23%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.51M
3.69%
+691.35K
+38.04%
Jun 30, 2025
Newtyn Management, LLC
1.71M
2.51%
+490.67K
+40.38%
Jun 30, 2025
State Street Investment Management (US)
2.70M
3.98%
+510.29K
+23.29%
Jun 30, 2025
Invesco Advisers, Inc.
1.33M
1.96%
-2.27M
-63.07%
Jun 30, 2025
American Century Investment Management, Inc.
1.92M
2.82%
+327.00K
+20.58%
Jun 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Tue, Dec 2
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Tue, Dec 2
์ด๋ฆ„
๋น„์œจ
State Street SPDR S&P Health Care Equipment ETF
1.75%
Invesco S&P SmallCap Health Care ETF
1.12%
Ballast Small/Mid Cap ETF
0.94%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.56%
JPMorgan Fundamental Data Science Small Core ETF
0.35%
State Street SPDR S&P 600 Small Cap Value ETF
0.26%
Avantis US Small Cap Value ETF
0.26%
iShares S&P Small-Cap 600 Value ETF
0.25%
iShares U.S. Medical Devices ETF
0.22%
State Street SPDR S&P SmallCap 600 ESG ETF
0.19%
๋” ๋ณด๊ธฐ
State Street SPDR S&P Health Care Equipment ETF
๋น„์œจ1.75%
Invesco S&P SmallCap Health Care ETF
๋น„์œจ1.12%
Ballast Small/Mid Cap ETF
๋น„์œจ0.94%
First Trust Nasdaq Lux Digi Health Solutions ETF
๋น„์œจ0.56%
JPMorgan Fundamental Data Science Small Core ETF
๋น„์œจ0.35%
State Street SPDR S&P 600 Small Cap Value ETF
๋น„์œจ0.26%
Avantis US Small Cap Value ETF
๋น„์œจ0.26%
iShares S&P Small-Cap 600 Value ETF
๋น„์œจ0.25%
iShares U.S. Medical Devices ETF
๋น„์œจ0.22%
State Street SPDR S&P SmallCap 600 ESG ETF
๋น„์œจ0.19%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

QuidelOrtho Corp์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
QuidelOrtho Corp์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค:
T. Rowe Price Investment Management, Inc.๋Š” 11.14M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 16.40%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
BlackRock Institutional Trust Company, N.A.๋Š” 9.28M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 13.67%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
The Vanguard Group, Inc.๋Š” 7.77M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 11.44%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Rubric Capital Management LP๋Š” 4.64M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 6.83%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Fidelity Management & Research Company LLC๋Š” 2.56M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 3.76%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.

QuidelOrtho Corp์˜ ์ƒ์œ„ 3๋Œ€ ์ฃผ์ฃผ ์œ ํ˜•์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
QuidelOrtho Corp์˜ ์ฃผ์š” ์ฃผ์ฃผ ์œ ํ˜• ์ƒ์œ„ 3๊ฐ€์ง€๋Š”
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.์ž…๋‹ˆ๋‹ค.

QuidelOrtho Corp(QDEL)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2025Q3 ๊ธฐ์ค€์œผ๋กœ, QuidelOrtho Corp์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 656๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 79.44M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 116.95%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q2 ๋Œ€๋น„ 1.32% ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

QuidelOrtho Corp์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
FY2025Q2 ๊ธฐ์ค€, QuidelOrtho Corp์˜ Labs ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ 369.70M๋กœ ์ „์ฒด ๋งค์ถœ์˜ 60.22%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
KeyAI
๎™